Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 17 of 17 for “"Crizotinib"”.
-
Cost-utility analysis of EML4-ALK fusion testing followed by treatment with crizotinib in patients with Non-Small Cell Lung Cancer (NSCLC)
… trial by Pfizer, Inc. demonstrated that crizotinib (Xalkori, Pfizer, Inc.) offers significant improvement in clinical outcomes as a second line therapy for the treatment of EML4-ALK fusion–positive non-small-cell lung cancer (NSCLC). In 2013, the US Food and Drug Administration (FDA) …
-
ALK in the pathogenesis of cancer
… non-small cell lung cancer (NSCLC) including crizotinib, alectinib, ceritinib, brigatinib and lorlatinib. To define a global landscape of resistance mechanisms, patient-centric studies require many pre- and post-treatment tumour specimens taken from a sufficient number of patients, which is …
-
Mechanisms Underlying The Sensitivity and Resistance of Gastric Cancer Cells to Met Inhibitors
… pathway that was activated by the MET inhibitor crizotinib in drug-sensitive human gastric cancer cells, and functional studies confirmed that crizotinib increased autophagy levels in the drug sensitive cells in a concentration-dependent manner. We then used chemical and molecular approaches to …
-
Anti-VEGF Therapy Modulates Immune Cell Infiltration and Function in Multiple Breast Cancer Models
… using the receptor tyrosine kinase inhibitor crizotinib, Furthermore, the combination of mcr84 and crizotinib decreased metastatic burden in animals with already disseminated disease. These findings suggest that mcr84 is a valid clinical candidate in breast cancer and its combination with …
-
Modelling RANBP2-ALK-rearranged Epithelioid Inflammatory Myofibroblastic Sarcoma
… CD30 expression and early relapse despite crizotinib treatment [1, 2]. This study aimed to generate and utilise models of eIMS to assess molecular-targeted therapeutic combinations to prevent and/or treat ALK inhibitor relapse. Two approaches were pursued to develop clinically relevant eIMS …
-
Investigating the Genomics and Heterogeneity of Childhood Non-Hodgkin Lymphoma
… survival, and the use of ALK inhibitors such as crizotinib have been used to successfully bridge relapsed or refractory ALCL patients to stem cell transplantation---however, resistance to both ALK inhibitors and Rituximab occurs in the clinic. Therefore, there is urgent need for less toxic …
-
Met inhibitors στον μη μικροκυτταρικό καρκίνο του πνεύμονα / Met inhibitors in non–small cell lung cancer
… και capmatinib (GEOMETRY mono-1), τον αναστολέα crizotinib (Co-MET), καθώς και το cabozantinib σε ασθενείς με επίκτητη αντίσταση (CAPTURE). Οι εκλεκτικοί MET αναστολείς (capmatinib, tepotinib) επιτυγχάνουν υψηλά ποσοστά αντικειμενικής ανταπόκρισης σε treatment-naïve ασθενείς, με κλινικά σημαντική …
-
Investigating the genome of Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma
… co-treatment in vitro with the ALK inhibitor crizotinib led to additive/synergistic anti-tumour activity suggesting this may be an appropriate combination therapy for future use in the circumvention of ALK inhibitor resistance. Indeed, crizotinib-resistant and sensitive ALCL cells were equally …
-
The Role of Ribosomal Maturation Proteins WBSCR22 and EMG1 Methyltransferase Activity in Cancer
… anti-metastatic combination therapy with crizotinib. Preliminary data show that sub lethal concentrations of crizotinib are sufficient to reduce uveal melanoma WBSCR22 catalytic mutant cell metastatic potential. Together, these data define WBSCR22 as a regulator of migration and …
-
Targeting c-met in sonic hedgehog medulloblastomas
… outperformed the c-MET inhibitors foretinib and crizotinib in impairing cell viability in both 2D and 3D cell models by inducing a strong apoptotic response, which was more prominent in TP53-/- MB SHH cells compared to TP53wt cells, where it showed primarily mitotic delay. We observed a complex …
-
Role of C-Met and Egfr In Acquired Resistance to Parp Inhibitors In Triple-Negative Breast Cancer
… cells and the combination of talazoparib and crizotinib (multi-kinase inhibitor that inhibits c-MET) results in synergistic inhibition of cellular proliferation in PARP inhibitor-resistant cells. However, depleting c-MET in PARP inhibitor resistant cells had limited effect on talazoparib …
-
Physicochemical and computational approaches for the prediction of the manufacturability of active pharmaceutical ingredients
… energy of two further APIs, palbociclib and crizotinib, are reported. In general, particles with regular shapes exhibit higher surface energies and a greater propensity to stick. The specific surface energy measured experimentally and total surface energy measured computationally have been …
-
Development of Novel Self-Immolative Linkers based on Fragmentation and Cyclisation Reactions for Targeted Therapeutic Applications
… con un agente citotóxico como un derivado de Crizotinib. Adicionalmente, en el Capítulo 5, hemos explorado el potencial de las reacciones de ciclación intramolecular para el desarrollo de nuevos conectores auto-inmoladores. En este sentido, hemos diseñado y estudiado una librería que nos ha …
-
Opportunities and challenges in oncology targeted drug development : an assessment of the use of prevalence and companion diagnostic performance thresholds to guide clinical trial strategies
… Several drugs, including vemurafenib and crizotinib have demonstrated these benefits along with commercial success. However, significant risk exists for the drug developer since approval may be threatened if they fail to meet unclear and differing yet parallel requirements for both the …
-
Design of smart linkers and their applications in controlled-release drug delivery systems
… has been applied to the controlled release of Crizotinib, a drug used for the treatment of metastatic lung cancer. Thus, blocking the Grob fragmentation pathway, the pro-drug is stable and intact; at the same time, activation of the pathway by removing the amine protecting group of …
-
The Dissociation of Sensory Integration and Associative Learning in Caenorhabditis elegans and the Molecular Mechanisms Leading to Memory Acquisition
The study of associative learning in C. elegans takes advantage of a genetically tractable organism with a fully mapped connectome, and with a simple nervous system compared with that of mammals. A learning deficient mutant found in a mutagenesis screen, lrn-2, was characterized and mapped to the …
-
Novel treatment strategy for ALK-positive Anaplastic Large Cell Lymphoma
… PDX-derived cell line from an ALK TKI-resistant (Crizotinib) patient tumour was sensitive to METTL3 inhibition and showed near synergistic effects with the second-generation ALK TKI, Brigatinib. Subsequently, to identify alternative potential treatment options, drugs that affect epigenetic …